Starý liek v novej indikácii schválil americký FDA

Pôvodne na liečbu glaukómu, teraz na podporu rastu očných rias.

Latisse contains the same main ingredient as Allergans Lumigan, on the market for glaucoma since 2001. Patients taking Lumigan found a side effect of the drug to be eyelash growth. The drug may also bring in $500 million annually by 2012, and the opportunity could be much larger longer term

New Drug For the Enhancement of Eyelashes Was Approved

Zdieľať?